New hope for lung cancer: combining immunotherapy with targeted local therapy
NCT ID NCT06840782
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial tests whether adding local treatments like radiation or surgery to standard immunotherapy can help people with oligometastatic non-small cell lung cancer live longer. About 124 participants will be randomly assigned to receive either immunotherapy alone or immunotherapy plus local treatments for all cancer spots. The study aims to see if the combination improves overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Radiation therapy (SBRT), interventional radiology, or minimally invasive surgery
- What this could lead to
- If successful, this could show that adding targeted local treatments to standard immunotherapy helps people with limited metastatic lung cancer live longer.
- What could go wrong
- This is a mid-stage trial with 124 participants, so results may not apply to all patients. Adding local treatments may increase side effects without improving survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Sainte-Catherine
RECRUITINGAvignon, Provence-Alpes-Côte d'Azur Region, 84000, France
-
Gustave Roussy
RECRUITINGVillejuif, Île-de-France Region, 94805, France
-
Institut de Radiothérapie du Sud de l'Oise
RECRUITINGCreil, Hauts-de-France, 60100, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.